<DOC>
	<DOCNO>NCT00005623</DOCNO>
	<brief_summary>RATIONALE : Cyproterone acetate may effective treatment hot flash follow surgical chemical castration prostate cancer . It yet know regimen cyproterone acetate effective hot flash . PURPOSE : Randomized phase III trial determine effectiveness cyproterone acetate treat patient hot flash follow surgical chemical castration prostate cancer .</brief_summary>
	<brief_title>Cyproterone Acetate Treating Hot Flashes Following Surgical Chemical Castration Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy cyproterone acetate patient hot flash follow bilateral orchiectomy medical castration prostate cancer . - Compare effectiveness two dos cyproterone acetate patient . - Determine safety regimen patient . - Determine impact regimen quality life patient . OUTLINE : This randomize , double-blind , placebo control study . Patients receive one two dose oral cyproterone acetate placebo 12 week , follow 6-9 month open label extension period patient receive cyproterone acetate . Quality life assess . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Prostate cancer patient undergone bilateral orchiectomy medical castration ( LHRH agonist drug ) experience hot flash Hot flash define : At least 3 4 moderate severe hot flash per day 21 per week baseline Present least 1 month prior study PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Greater 12 month Hematopoietic : WBC least 3,000/uL Platelet count least 75,000/uL Hemoglobin least 6.2 mmol/L Hepatic : Bilirubin great 1.8 mg/dL SGPT great 96 u/L SGOT great 90 u/L LDH great 600 Renal : BUN great 42 mg/dL Creatinine great 3.39 mg/dL Cardiovascular : No cardiovascular risk ( e.g. , history angina pectoris ) unless control medical surgical therapy No known history thromboembolic disease Other : Comprehend understand English language No prior malignancy within past 5 year except treat squamous basal cell skin cancer superficial bladder carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week washout period require prior antineoplastic cytotoxic chemotherapy use Endocrine therapy : At least 4 week washout period require prior estrogen , antiandrogens ( e.g. , flutamide bicalutamide ) , progestational agent , corticosteroid use No concurrent herbal medication know hormonal ingredient ( i.e. , phytoestrogens ) Radiotherapy : Not specify Surgery : See Disease Characteristics Other : At least 4 week washout period require prior clonidine monoamine oxidase inhibitor use</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>hot flash</keyword>
</DOC>